ArticleMolecular biomedicine2026
Plasma proteomics-based liquid biopsy for predicting efficacy of PD-1-based immunochemotherapy in advanced gastric cancer: a prospective cohort study.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The combination of immune checkpoint inhibitors (ICIs) and chemotherapy has become the standard first-line treatment for advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC), yet reliable biomarkers predicting efficacy remain limited. We performed longitudinal plasma proteomic profiling in 31 patients receiving immunochemotherapy in this prospective observational cohort study. Serial plasma samples collected at baseline and every two treatment cycles were analyzed to identify dynamic protein changes correlated with therapeutic response and survival. The results showed that responders exhibited significantly lower baseline interleukin-15 (IL-15) levels (P = 0.01). After two cycles of treatment, a 161.9% reduction in plasma Mucin-16 (MUC-16), also known as Cancer Antigen-125 (CA-125), was identified as an independent factor for prolonged overall survival (HR 7.40, 95%CI 2.22-24.60, P = 0.001), which was validated by conventional serum CA-125 testing. Integrating baseline IL-15 with dynamic changes in MUC-16 and Matrix Metalloproteinase 12 (MMP12), the constructed composite risk model achieved an Area Under the Curve (AUC) of 0.799 for predicting response, and this model was also an independent factor for progression-free survival (HR 3.35, 95% 1.56-7.20, P = 0.002). In summary, baseline IL-15 helps identify patients likely to benefit from immunochemotherapy, while MUC-16 and the integrated model facilitate dynamic monitoring of therapeutic efficacy. These findings provide new insights into non-invasive blood-based patient stratification and treatment optimization.Trial registration ChiCTR2300078000. Registered 27 November 2023-prospectively registered, https://www.chictr.org.cn/hvshowproject.html?id=241839&v=1.0.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.